Patent application number | Description | Published |
20080214524 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR - Compounds of formula (I) | 09-04-2008 |
20080287676 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR - The present invention discloses novel compounds of general formula (I) | 11-20-2008 |
20090062345 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS - The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, | 03-05-2009 |
20090124671 | TRPV1 ANTAGONISTS - The present invention relates to compounds of formula (I) | 05-14-2009 |
20090233953 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF - The present invention is directed to compounds of formula (I) | 09-17-2009 |
20100120846 | TRPV1 ANTAGONISTS - Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, | 05-13-2010 |
20100137360 | TRPV1 ANTAGONISTS - Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, | 06-03-2010 |
20110082170 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF - The present invention discloses fused thienopyridyl compounds of general formula (I) | 04-07-2011 |
20110288129 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS - The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, | 11-24-2011 |
20120022103 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF - The present application is directed to compounds that are TRPV1 antagonists and have formula (I) | 01-26-2012 |
20120277190 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR - Compounds of formula (I) | 11-01-2012 |
20130165479 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF - The present application is directed to compounds that are TRPV1 antagonictc and have formula (I) | 06-27-2013 |